Background: Blood eosinophil count (bEOS) is an important biomarker in obstructive lung disease. NOVELTY (NCT02760329) is a global, prospective, observational study with potential to identify obstructive lung disease phenotypes associated with differential outcomes, using biomarkers and clinical features. Objective: To evaluate factors associated with bEOS in patients with either physician-assigned asthma or COPD in NOVELTY.
|Publication status||Accepted/In press - 27 Jul 2020|
|Event||30th ERS International Congress - Virtual Event|
Duration: 7 Sep 2020 → 9 Sep 2020
|Conference||30th ERS International Congress|
|Period||7/09/20 → 9/09/20|